BioSig Technologies (NASDAQ:BSGM) Price Target Raised to $10.00

BioSig Technologies (NASDAQ:BSGM - Free Report) had its price target hoisted by Ascendiant Capital Markets from $2.50 to $10.00 in a research note issued to investors on Friday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

BioSig Technologies Stock Performance

BioSig Technologies stock traded up $1.59 during mid-day trading on Friday, hitting $7.33. The company's stock had a trading volume of 3,022,169 shares, compared to its average volume of 319,881. The business has a 50 day moving average price of $2.34 and a 200-day moving average price of $1.56. BioSig Technologies has a 12 month low of $0.20 and a 12 month high of $8.70.

BioSig Technologies (NASDAQ:BSGM - Get Free Report) last released its earnings results on Monday, May 19th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). Research analysts expect that BioSig Technologies will post -0.88 EPS for the current year.

Hedge Funds Weigh In On BioSig Technologies

A number of hedge funds have recently modified their holdings of the company. Integrity Wealth Advisors Inc. bought a new stake in BioSig Technologies during the fourth quarter worth about $61,000. Geode Capital Management LLC purchased a new position in shares of BioSig Technologies in the fourth quarter valued at $143,000. Millennium Management LLC bought a new stake in shares of BioSig Technologies in the 4th quarter valued at approximately $228,000. PFG Investments LLC lifted its stake in BioSig Technologies by 43.5% in the first quarter. PFG Investments LLC now owns 158,286 shares of the company's stock worth $95,000 after purchasing an additional 48,000 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its stake in shares of BioSig Technologies by 966.3% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 266,435 shares of the company's stock valued at $160,000 after buying an additional 241,447 shares during the period. Hedge funds and other institutional investors own 7.16% of the company's stock.

About BioSig Technologies

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.